Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Value of GCDFP-15 (BRST-2) as a Specific Immunocytochemical Marker for Breast Carcinoma in Cytologic Specimens

Acta Cytologica (1996) 40 (4): 637–641.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Generation of prolactin-inducible protein (Pip) knockout mice by CRISPR/Cas9-mediated gene engineering
  • Lucas E.L. Terceiro
  • Anne A.A. Blanchard
  • Chidalu A. Edechi
  • Agnes Freznosa
  • Barbara Triggs-Raine
  • Etienne Leygue
  • Yvonne Myal
Canadian Journal of Physiology and Pharmacology (2022) 100 (1): 86.
Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis
  • Lyndsey S. Crump
  • Kelsey T. Kines
  • Jennifer K. Richer
  • Traci R. Lyons
American Journal of Physiology-Cell Physiology (2022) 323 (5): C1475.
Immunohistochemistry Applied to Breast Cytological Material
  • Daniel Pinto
  • Fernando C. Schmitt
Pathobiology (2022) 89 (5): 343.
Breast carcinoma metastasising to the gastric wall and the peritoneum: what physicians need to know
  • Abdullah Sohail
  • Ahmad Khan
  • Alexander Gross
  • Hamza Shah
BMJ Case Reports (2021) 14 (5): e241467.
Secreted indicators of androgen receptor activity in breast cancer pre-clinical models
  • Toru Hanamura
  • Jessica L. Christenson
  • Kathleen I. O’Neill
  • Emmanuel Rosas
  • Nicole S. Spoelstra
  • Michelle M. Williams
  • Jennifer K. Richer
Breast Cancer Research (2021) 23 (1)
The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer
  • Chidalu A. Edechi
  • Nnamdi M. Ikeogu
  • Gloria N. Akaluka
  • Lucas E. L. Terceiro
  • Mikayla Machado
  • Enitan S. Salako
  • Aida F. Barazandeh
  • Sam K. P. Kung
  • Jude E. Uzonna
  • Yvonne Myal
Frontiers in Oncology (2021) 11
The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages
  • Olivia Ihedioha
  • Anne A. Blanchard
  • Jyoti Balhara
  • Ifeoma Okwor
  • Ping Jia
  • Jude Uzonna
  • Yvonne Myal
Immunologic Research (2018) 66 (2): 245.
Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator—Novel Insights from Knockout Mice
  • Olivia C. Ihedioha
  • Robert P.C. Shiu
  • Jude E. Uzonna
  • Yvonne Myal
DNA and Cell Biology (2016) 35 (10): 537.
A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know
  • Forat Swaid
  • Darrell Downs
  • Alexander S. Rosemurgy
Cancer Genetics (2016) 209 (12): 559.
GATA3: A promising marker for metastatic breast carcinoma in serous effusion specimens
  • Paul W. Shield
  • David J. Papadimos
  • Michael D. Walsh
Cancer Cytopathology (2014) 122 (4): 307.
Significance of immunohistochemistry in breast cancer
  • Dana Carmen Zaha
World Journal of Clinical Oncology (2014) 5 (3): 382.
Immunocytochemistry: an indispensable technique in routine cytology
  • L. Skoog
  • E. Tani
Cytopathology (2011) 22 (4): 215.
Generation and initial characterization of the prolactin-inducible protein (PIP) null mouse: accompanying global changes in gene expression in the submandibular glandThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.
  • A. Blanchard
  • A. Nistor
  • F.E. Castaneda
  • D. Martin
  • G.G. Hicks
  • F. Amara
  • R.P.C. Shiu
  • Y. Myal
Canadian Journal of Physiology and Pharmacology (2009) 87 (10): 859.
A Functional and Regulatory Network Associated with PIP Expression in Human Breast Cancer
  • Marie-Anne Debily
  • Sandrine El Marhomy
  • Virginie Boulanger
  • Eric Eveno
  • Régine Mariage-Samson
  • Alessandra Camarca
  • Charles Auffray
  • Dominique Piatier-Tonneau
  • Sandrine Imbeaud
  • Alfredo Herrera-Estrella
PLoS ONE (2009) 4 (3): e4696.
Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
  • Suzuko Moritani
  • Shu Ichihara
  • Masaki Hasegawa
  • Tokiko Endo
  • Mikinao Oiwa
  • Kazuaki Yoshikawa
  • Yasuyuki Sato
  • Hideaki Aoyama
  • Takako Hayashi
  • Ryoji Kushima
Human Pathology (2008) 39 (5): 666.
Gross Cystic Disease Fluid Protein—(GCDFP-15)
  • Joan M. Striebel
  • Sanja Dacic
  • Samuel A. Yousem
American Journal of Surgical Pathology (2008) 32 (3): 426.
Metastatic Carcinoma in Effusions
  • Armando C. Filie
  • Heather D. Jones
Pathology Case Reviews (2006) 11 (2): 74.
Pathology of Liver Metastases
  • Barbara A. Centeno
Cancer Control (2006) 13 (1): 13.
The Diagnosis of Malignancy in Effusion Cytology: A Pattern Recognition Approach
  • Telma C. Pereira
  • Reda S. Saad
  • Yulin Liu
  • Jan F. Silverman
Advances in Anatomic Pathology (2006) 13 (4): 174.
Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations
  • Jonathan L. Hecht
  • Jack L. Pinkus
  • Geraldine S. Pinkus
Cancer (2005) 108 (1): 56.
The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis
  • J W Clark
  • L Snell
  • R P C Shiu
  • F W Orr
  • N Maitre
  • C P H Vary
  • D J Cole
  • P H Watson
British Journal of Cancer (1999) 81 (6): 1002.
Circulating antibodies against the breast tumor marker GCDFP-15/gp17 in mammary carcinoma patients and in patients carrying benign breast conditions
  • Rosa Pasquinelli
  • Pasquale Barba
  • Immacolata Capasso
  • Massimiliano D'Aiuto
  • Giuseppe D'Aiuto
  • Anna Maria Anzisi
  • Piergiuseppe De Berardinis
  • John Guardiola
International Journal of Cancer (1999) 84 (6): 568.
  • Online ISSN 1938-2650
  • Print ISSN 0001-5547
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal